Nuclear Medicine Partnership NRG PALLAS’s core focus on nuclear medicine and radiopharmaceutical materials presents sales opportunities with medical research organizations, hospitals, and pharma companies seeking reliable suppliers of lead-212, lutetium-177 chloride, and Mo-99 via collaborations with partners like TAG1, Morpho Pharma, and Curium.

Petten Expansion The ongoing Pallas reactor project in Petten, Netherlands, and selection of Framatome for the FRPS indicate a growing footprint in nuclear research infrastructure. This opens up cross-sell opportunities around safety systems, irradiation services, and supply chain solutions for new facilities.

Strategic Partnerships Active multi-year collaborations with Curium, TAG1, and Morpho Pharma demonstrate a proven model for joint development and independent supply chains. This suggests potential for expanded co-development deals, exclusive supply agreements, and regional distribution partnerships.

Energy and Health Synergy NRG PALLAS’s dual pillars of nuclear medicine and CO2-neutral energy create cross-industry selling points to energy and healthcare funders, universities, and government programs seeking integrated solutions for health outcomes and climate initiatives.

Growth and Funding Signals A revenue range of 50 to 100 million USD and a workforce of over a thousand indicate scale and stability, enabling conversations with larger pharma, research consortia, and energy customers about expanded procurement, long-term framework agreements, and strategic collaborations.